Company / Tangible Book Value per Share
CRISPR Therapeutics AG Tangible Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
$20.04
FY2025
5-year range
$20.04 / $31.17
FY2021-FY2025
Trend
-11.1%
vs FY2024
Sector context
#25 of 209
Health Care
What the data says
CRISPR Therapeutics AG's tangible book value per share of $20.04 is higher than 88% of companies in the Health Care sector (FY2025). Tangible Book Value per Share has declined for 4 consecutive years, from $31.17 in FY2021 to $20.04 in FY2025.
Based on SEC 10-K filings.
20.04 in FY2025 with a 5-year CAGR of -2.3%. Top quartile in the Health Care sector.
Declined from $23.52 to $20.04 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -2.3%
- 10-Year CAGR
- -
Sector benchmark
-78.5% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's tangible book value per share has declined for 4 consecutive years.
- In FY2025, tangible book value per share decreased 11.1% year-over-year.
- Ranks #25 out of 209 companies in the Health Care sector.
- Peak tangible book value per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.04 | -11.1% |
| FY2024 | $22.53 | -4.2% |
| FY2023 | $23.52 | -1.5% |
| FY2022 | $23.89 | -23.4% |
| FY2021 | $31.17 | +38.4% |
| FY2020 | $22.52 | +24.3% |
| FY2019 | $18.12 | +291.5% |
| FY2018 | $4.63 | -21.1% |
| FY2017 | $5.86 | -86.1% |
| FY2016 | $42.12 | +828.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026